A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma

BACKGROUND: The patient population with stage III non-small-cell lung cancer (NSCLC) is heterogeneous, with varying staging characteristics and diverse treatment options. Despite the potential practice-changing implications of randomized controlled trials evaluating the efficacy of perioperative epi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chieh-Lung, Wang, Sing-Ting, Liao, Wei-Chih, Chen, Chia-Hung, Tu, Chih-Yen, Hsia, Te-Chun, Cheng, Wen-Chien, Chen, Hung-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496373/
https://www.ncbi.nlm.nih.gov/pubmed/37697233
http://dx.doi.org/10.1186/s12885-023-11342-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496373/
https://www.ncbi.nlm.nih.gov/pubmed/37697233
http://dx.doi.org/10.1186/s12885-023-11342-y

Ejemplares similares